Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0371319920420020171
Journal of the Korean Surgical Society
1992 Volume.42 No. 2 p.171 ~ p.178
The Hematologic Toxicity of MFC Chemotherapy following Surgery for Gastric Cancer



Abstract
MFC combination therapy had a marked synergistic effect and clinically used against gastric cancer.
But, MFC therapy had some toxicity and the main toxity was bone marrow supression and gastrointestinal symptom.
This report is a study about the hematologic toxicity of MFC chemotherapy following surgery for gastric cancer. The studied subjects were 168 cases treated with MFC chemotherapy along its full regimen among 353 gastric cancer patients surgically
treated
between January 1986 and December 1988 at the department of Surgery, Christian Hospital, Kwangju.
@ES The results are as follows;
@EN 1) The range of age of patients were from 21 to 80 years of age. The peak age group was in the 6th decade with 69 cases(41.1%). The ratio of male to female was 2.5 : 1.
2) In TNM staging of gastric cancer, stage I was 13 cases(7.7%), stage II was 7 cases(4.2%), stage III was 102 cases(60.7%), and stage IV was 47 cases(27.4%).
3) The curative operation was performed in 113 cases(67.3%), and palliative operation in 55 cases(32.7%).
4) The toxicity of MFC chemotherapy was noted in 141 cases(83.9%), and the hematologic toxicity such as leukocytopenia and thrombocytopenia was noted in 121 cases(72.0%).
5) In the hemetologic toxicity, leukocytopenia was noted in 120 cases(71.4%); leukocyte counts were 3000~4000/§§ in 104 cases(61.9%) and 2000~3000/§§ in 16 cases(9.5%). The time leukocytopenia was most frequently ocurred was 4 times and average
duration was 4.3 weeks.
6) In the hematologic toxicity, thrombocytopenia was noted in 15 cases(8.9%); platelet counts were 50,000~100,000/§© in all cases. The time thrombocytopenia was most frequently noted was 5 times and average duration was 1.5 weeks.
7) The hematologic toxicity was noted 76.9% among stage I, 71.4% among stage II, 74.5% among stage III, and 65.2% among stage IV. The hematologic toxicity was noted 74.3% among curative operation group and 67.3% among palliative operation group.
Therefore, the hematologic toxicity of MFC chemotherapy was not significantly related to TMN stage and the type of operation.
KEYWORD
FullTexts / Linksout information
 
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø